Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 1:39 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 90 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Drug Abilify Clear all
Terminated Phase 4 Interventional

An Exploratory Analysis of Immune and Inflammatory Response Associated With Clozapine

NCT05741502
View directory record Official record
Conditions
Treatment-resistant Schizophrenia
Interventions
Clozapine, Antipsychotics,Other (non-Clozapine)
Drug
Lead sponsor
Ohio State University
Other
Eligibility
18 Years to 65 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 25, 2026 · Synced Oct 15, 2026, 1:39 AM EDT
Completed Phase 3 Interventional Results available

The Combination of Aripiprazole and Antidepressants in Psychotic Major Depression

NCT00556140
View directory record Official record
Conditions
Psychotic Depression
Interventions
Aripiprazole
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 80 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 20, 2012 · Synced Oct 15, 2026, 1:39 AM EDT
Terminated Phase 3 Interventional Results available

Estimating and Reducing the Cardiovascular Risk of Patients With Schizophrenia Drugs From Lipid Measures and Ischemic Electrocardiographic Changes

NCT00288353
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Bipolar Disorder
Interventions
aripiprazole (Abilify), ziprasidone (Geodon)
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 2, 2025 · Synced Oct 15, 2026, 1:39 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug Interaction Study With Famotidine, Atazanavir, and Atazanavir/Ritonavir/Tenofovir

NCT00365339
View directory record Official record
Conditions
HIV Infections
Interventions
Atazanavir+Ritonavir+Tenofovir, Atazanavir+Ritonavir+Tenofovir+Famotidine
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 50 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
Hamilton, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 8, 2011 · Synced Oct 15, 2026, 1:39 AM EDT
Completed Phase 1 Interventional

Parallel Group, Multiple Dose Pharmacokinetics Study of Five Antipsychotic Medications in Psychiatric Participants

NCT02087579
View directory record Official record
Conditions
Psychotic Disorders, Schizophrenia, Bipolar Disorder, Depressive Disorder
Interventions
Aripiprazole, oral formulation, Olanzapine, oral formulation, Paliperidone, oral formulation, Paliperidone, LAI, Quetiapine, oral formulation, Risperidone, oral formulation, Risperidone, LAI
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 70 Years
Enrollment
305 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
6
States / cities
Garden Grove, California • Kissimmee, Florida • Atlanta, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2015 · Synced Oct 15, 2026, 1:39 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Aripiprazole as Augmentation for TRD

NCT00174876
View directory record Official record
Conditions
Depression
Interventions
Drug Abilify
Drug
Lead sponsor
State University of New York - Upstate Medical University
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2005
U.S. locations
1
States / cities
Syracuse, New York
Source: ClinicalTrials.gov public record
Updated Sep 18, 2008 · Synced Oct 15, 2026, 1:39 AM EDT
Completed Phase 4 Interventional Results available

Preventing Relapse in Schizophrenia: Oral Antipsychotics Compared To Injectables: Evaluating Efficacy

NCT00330863
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Risperidone microspheres, Risperidone, Olanzapine, Quetiapine, Ziprasidone, Aripiprazole, Paliperidone
Drug
Lead sponsor
Northwell Health
Other
Eligibility
18 Years to 65 Years
Enrollment
357 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
8
States / cities
Los Angeles, California • Augusta, Georgia • Iowa City, Iowa + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2018 · Synced Oct 15, 2026, 1:39 AM EDT
Completed Phase 3 Interventional Results available

A Study of Aripiprazole Lauroxil or Paliperidone Palmitate for the Treatment of Schizophrenia

NCT03345979
View directory record Official record
Conditions
Schizophrenia
Interventions
Aripiprazole Lauroxil, Paliperidone Palmitate
Combination Product · Drug
Lead sponsor
Alkermes, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
16
States / cities
Little Rock, Arkansas • Rogers, Arkansas • Cerritos, California + 13 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2020 · Synced Oct 15, 2026, 1:39 AM EDT
Completed Not applicable Interventional

A Prospective Trial to Assess Cost and Clinical Outcomes of a Clinical Pharmacogenomic Program

NCT02297126
View directory record Official record
Conditions
Adverse Drug Reaction
Interventions
Pharmacogenetic Intervention Arm (pharmacogenetic testing)
Other
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
4,465 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jan 8, 2021 · Synced Oct 15, 2026, 1:39 AM EDT
Completed Not applicable Interventional Results available

Double-Blind Placebo Controlled Study of Adjunctive Aripiprazole for Symptomatic Hyperprolactinemia In Premenopausal Women With Schizophrenia

NCT01338298
View directory record Official record
Conditions
Hyperprolactinemia
Interventions
Aripiprazole, Placebo
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Catonsville, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 27, 2019 · Synced Oct 15, 2026, 1:39 AM EDT
Completed Phase 3 Interventional Results available

Aripiprazole Effects on Alcohol Drinking and Craving

NCT01292057
View directory record Official record
Conditions
Alcohol Dependence
Interventions
Aripiprazole, Placebo
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
21 Years to 40 Years
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Aug 8, 2017 · Synced Oct 15, 2026, 1:39 AM EDT
Completed Phase 2 Interventional Results available

A Study to Assess the Safety and Efficacy of ASP4345 as Add-on Treatment for Cognitive Impairment in Subjects With Schizophrenia on Stable Doses of Antipsychotic Medication

NCT03557931
View directory record Official record
Conditions
Schizophrenia
Interventions
ASP4345, placebo, risperidone, quetiapine, olanzapine, ziprasidone, aripiprazole, brexpiprazole, paliperidone, lurasidone
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
233 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
27
States / cities
Cerritos, California • Garden Grove, California • Lemon Grove, California + 19 more
Source: ClinicalTrials.gov public record
Updated Nov 12, 2024 · Synced Oct 15, 2026, 1:39 AM EDT
Terminated Phase 2 Interventional Results available

A Study to Assess the Clinical Utility of Antipsychotic Medication Levels in Plasma as Determined by Liquid Chromatography-Tandem Mass Spectrometry

NCT02462473
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Aripiprazole, Olanzapine, Paliperidone, Quetiapine, Risperidone
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 70 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
3
States / cities
Torrance, California • Kissimmee, Florida • Conshohocken, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 29, 2017 · Synced Oct 15, 2026, 1:39 AM EDT
Completed No phase listed Observational

Observational Study of Long Acting Injectable Medications (LAIs) in Schizophrenia (OASIS)

NCT03919994
View directory record Official record
Conditions
Schizophrenia
Interventions
Not listed
Lead sponsor
Alkermes, Inc.
Industry
Eligibility
18 Years and older
Enrollment
338 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
57
States / cities
Tucson, Arizona • Costa Mesa, California • El Cajon, California + 49 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2023 · Synced Oct 15, 2026, 1:39 AM EDT
Completed Not applicable Interventional Results available

Efficacy of Aripiprazole Versus Placebo in the Reduction of Aggressive and Aberrant Behavior in Autistic Children

NCT00468130
View directory record Official record
Conditions
Autism
Interventions
Aripiprazole, Placebos
Drug
Lead sponsor
University of Medicine and Dentistry of New Jersey
Other
Eligibility
5 Years to 17 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Piscataway, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 14, 2022 · Synced Oct 15, 2026, 1:39 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Examining the Effects of Antipsychotic Medications on Insulin Sensitivity

NCT00895921
View directory record Official record
Conditions
Diabetes
Interventions
Olanzapine, Aripiprazole
Drug
Lead sponsor
Veterans Medical Research Foundation
Other
Eligibility
40 Years to 65 Years · Male only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Aug 11, 2020 · Synced Oct 15, 2026, 1:39 AM EDT
Terminated Not applicable Interventional Results available

Aripiprazole, Abilify Maintena Collaborative Clinical Protocol

NCT02717130
View directory record Official record
Conditions
Schizophrenia
Interventions
Aripiprazole
Drug
Lead sponsor
Florida Atlantic University
Other
Eligibility
18 Years to 65 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
4
States / cities
Columbia, Missouri • Kansas City, Missouri • Springfield, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2020 · Synced Oct 15, 2026, 1:39 AM EDT
Completed Phase 3 Interventional Results available

A Double-Blind, Placebo-Controlled Study of Aripiprazole Adjunctive to Antidepressant Therapy

NCT00683852
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Aripiprazole 5mg, Aripiprazole 2mg, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 19, 2017 · Synced Oct 15, 2026, 1:39 AM EDT
Completed Phase 3 Interventional

A Study of Adjunctive Aripiprazole in Participants With Major Depressive Disorder

NCT00095758
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Antidepressant + Placebo, Antidepressant + Aripiprazole
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
1,151 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
28
States / cities
Beverly Hills, California • Burbank, California • National City, California + 25 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Oct 15, 2026, 1:39 AM EDT
Completed Phase 4 Interventional Results available

Biomarkers in Autism of Aripiprazole and Risperidone Treatment (BAART)

NCT01333072
View directory record Official record
Conditions
Autistic Disorder
Interventions
Aripiprazole, Risperidone
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
6 Years to 17 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Sep 26, 2018 · Synced Oct 15, 2026, 1:39 AM EDT
Not yet recruiting Not applicable Interventional

Evaluating the Impact of Ketogenic Therapy on Symptom Severity and Metabolic Side Effect Profile Among Individuals Living With Bipolar Disorder in A Rural Southern Catchment Area

NCT07570875
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Ketogenic foodstuffs, Standard of Care Oral antipsychotics, Standard of care long acting injectable medication for bipolar disorder
Dietary Supplement · Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Montgomery, Alabama
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 15, 2026, 1:39 AM EDT
Completed No phase listed Observational

Long-term Antipsychotic Pediatric Safety Trial

NCT03522168
View directory record Official record
Conditions
Weight, Body
Interventions
Risperidone, Aripiprazole
Drug
Lead sponsor
Duke University
Other
Eligibility
3 Years to 18 Years
Enrollment
509 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
37
States / cities
Dothan, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 32 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2026 · Synced Oct 15, 2026, 1:39 AM EDT
Completed Not applicable Interventional Results available

Early Detection and Intervention for the Prevention of Psychosis

NCT00531518
View directory record Official record
Conditions
Schizophrenia, Bipolar Disorder, Depression, Psychotic Disorders
Interventions
aripiprazole; fluoxetine; bupropion; sertraline; lamotrigine, Psychoeducational multifamily group treatment, Supported employment and education
Drug · Behavioral
Lead sponsor
MaineHealth
Other
Eligibility
12 Years to 25 Years
Enrollment
292 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
6
States / cities
Sacramento, California • Portland, Maine • Ann Arbor, Michigan + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 15, 2016 · Synced Oct 15, 2026, 1:39 AM EDT
Completed Phase 1 Interventional

Reducing Antipsychotic-Induced Weight Gain in Children With Metformin

NCT01231074
View directory record Official record
Conditions
Obesity, Weight Gain, Psychotropic Induced Weight Gain
Interventions
Metformin
Drug
Lead sponsor
Nationwide Children's Hospital
Other
Eligibility
10 Years to 17 Years
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 2, 2019 · Synced Oct 15, 2026, 1:39 AM EDT